SCHEMBL14949265

SCHEMBL14949265

CCOc1cc(Oc2ccc(-c3nnc(Nc4cccc(C)c4C)[nH]3)cc2)nc(N)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 3/20 0.38
DHFR P00374 1/20 0.37
RAB9A P51151 5/20 0.36
ALDH1A1 P00352 5/20 0.36
NPC1 O15118 4/20 0.36
MAPK1 P28482 1/20 0.36
SMN1; SMN2 Q16637 5/20 0.36
JAK2 O60674 1/20 0.36
TNF P01375 1/20 0.36
HTT P42858 1/20 0.36
NOD1 Q9Y239 1/20 0.36
SRC P12931 1/20 0.33
MAPT P10636 4/20 0.32
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
HPGD P15428 3/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12336573 0.88 PDGFRB (0.34) NUDT1DHFRRAB9AALDH1A1NPC1
SCHEMBL14949252 0.85 DHFR (0.35) NUDT1DHFRRAB9AALDH1A1NPC1
SCHEMBL14949247 0.84 RAB9A (0.37) NUDT1RAB9AALDH1A1NPC1MAPK1
SCHEMBL14949248 0.84 SMN1; SMN2 (0.38) NUDT1RAB9AALDH1A1NPC1MAPK1
SCHEMBL14949254 0.83 RAB9A (0.38) NUDT1RAB9AALDH1A1NPC1MAPK1
SCHEMBL14949246 0.83 SMN1; SMN2 (0.38) NUDT1RAB9AALDH1A1NPC1MAPK1
SCHEMBL14949504 0.80 KDR (0.38) NUDT1RAB9AALDH1A1NPC1MAPK1
SCHEMBL627480 0.80 PDGFRB (0.49) NUDT1DHFRRAB9ANPC1JAK2
SCHEMBL12336276 0.80 PDGFRB (0.49) ALDH1A1HTTMAPTLMNAKDM4E
SCHEMBL14949331 0.76 RAB9A (0.39) NUDT1RAB9AALDH1A1NPC1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 US disclosed
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION MAP4K2, MAP3K20, MAP3K19 NUDT1 1966/4885DHFR 1841/4885RAB9A 1281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.